Symbol:  Markets Quote Level II Charts News Filings Streamer

Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version Business Summary: Aida Pharmaceuticals, Inc. and its subsidiaries engage in the development, production, and distribution of antibiotics, cardiovascular, and anti cancer drugs in the People's Republic of China.   Address   31 Dingjiang Rd   Hangzhou 310016   Phone: 86-0571-85802712   Website: http://www.aidapharma.com Auditor   Weinberg & Company   Boca Raton , FL Transfer Agent   OTC Stock Transfer, Inc. Employees:  450 ShareHolders:  50 Founded:  2002 Domicile:  Nevada      S & P Disclaimer   Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version Aida Pharmaceuticals, Inc. and its subsidiaries engage in the development, production, and distribution of antibiotics, cardiovascular, and anti cancer drugs in the People's Republic of China. It offers products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate for the treatment of various inflammations, including respiratory infection, such as acute bronchitis, acute onset of chronic bronchitis, and pulmonary infections; kidney and urinogenital infection comprising acute pyelonephritis or acute onset of chronic cystitis; soft skin tissue infection; and trauma and operations. Its products under development include Apoptotic Factor (Rh-Apo2l), a cancer therapeutic, which is in Phase II clinical trials; Vasostatin Apo2L, a cancer drug that is under preclinical research; Prodigiosin, a naturally occurring red pigment, which is in pre-clinical trials for the treatment of pancreatic cancer; Anti-CD86 Monoclonal Antibody that is under preclinical research to inhibit T-cells from harming healthy tissue; and Anti-CTLA-4 monoclonal antibody to inhibit tumor growth. The company was founded in 1999 and is headquartered in Hangzhou, the People's Republic of China. History:  INCORPORATED in Nevada Dec. 18, 2002, as BAS Consulting, Inc.; name changed to Aida Pharmaceuticals, Inc. Feb. 24, 2006. On Dec. 8, 2005, the company acquired Earjoy Group Limited for 23,375,000 Common shares.   Subsidiaries: Changzhou Fangyuan Pharmaceutical Co., Ltd. Earjoy Group Limited Hainan Aike Pharmaceutical Co., Ltd. Hangzhou Aida Pharmaceutical Co., Ltd. Hangzhou Boda Medical Research and Development Co., Ltd. Shanghai Qiaer Bio-Technology Co., Ltd. Yangpu Aike Pharmaceutical Co., Ltd.     Capital Expenditures, thousand. US Dollars   Year   Amount   2007   2,967   2006   712   2005   700   Research and Development Expenditures, thousand. US Dollars   Year   Amount   2007   284   2006   325   2005   39      S & P Disclaimer   Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version Management Officers Position  Jin  Biao Chairman & Chief Executive Officer  Lin  Hui Chief Financial Officer & Chief Accounting Officer  Yuejun  Jiang Secretary Directors  Jin  Biao  Qiu  Jiajun  Zhang  Qiong      S & P Disclaimer   Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version   Capitalization as of 03/31/2008:     Authorized Shares Outstanding Shares Common $0.001 par 75,000,000 27,000,000   LONG TERM DEBT: $6,835,465.   Common $0.001 par   Stockholders:  03/14/2008, 50. PRINCIPAL STOCKHOLDERS: March 27, 2008, Union Zone Management Ltd. owned or controlled 51.9% of the Common, Panasia Strategy Investment Co. Ltd. 16.6%, Cede & Co 9.6% and Winsummit China Growing Holdings, Ltd. 6.6%.   Transfer Agent:  OTC Stock Transfer, Inc.   Salt Lake City , UT   OTC Bulletin Board( Primary): AIDA   Exchange Year High Low OTC Bulletin Board 2007 2.1900 0.8100 OTC Bulletin Board 2006 2.0000 0.7000 OTC Bulletin Board 2005 3.8599 1.0936   DIVIDENDS: Common $0.001 par: No cash. Common reverse split 1-for-6.433138, Nov. 30, 2005.        S & P Disclaimer   Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version Annual Report   Income Statement   2007 2006 REVENUES, NET $29,203,786 $29,643,103 COST OF GOODS SOLD 14,510,682 14,081,040 GROSS PROFIT 14,693,104 15,562,063 Research and development 284,230 324,835 Selling and distribution 4,731,711 5,581,681 General and administrative 4,231,917 5,719,269 INCOME FROM OPERATIONS 5,445,246 3,936,278 Interest expense, net (2,022,093) (1,703,200) Government grants 113,189 169,439 Forgiveness of debt 114,173 - Return of sales commission 995,603 - Gain on sale of marketable securities 121,998 - Other expense, net (84,763) (79,920) INCOME FROM OPERATIONS BEFORE INCOME TAXES 4,683,353 2,322,597 INCOME TAXES (360,041) (173,258) MINORITY INTERESTS (1,583,487) (695,755) NET INCOME 2,739,825 1,453,584 NET INCOME PER SHARE, BASIC AND DILUTED $0.10 $0.06   Balance Sheet   2007 2006 ASSETS CURRENT ASSETS Cash and cash equivalents $8,399,306 $6,116,816 Restricted cash 885,743 1,983,237 Accounts receivable, net 9,661,421 13,777,571 Notes receivable, net 987,489 2,714,234 Inventories 3,837,659 2,806,945 Due from related parties 19,889 41,462 Other receivables, prepaid expenses, and other assets 182,289 146,694 Marketable securities - 362,758 Due from employees 1,014,395 264,182 Prepayments for goods 324,370 118,327 Deposits 10,553,431 953,267 Deferred taxes 414,854 295,714 Total current assets 36,280,846 29,581,207 Plant and equipment, net 16,752,638 13,977,611 Land use rights, net 3,664,715 3,747,225 Construction in progress 269,552 28,430 Patents, net 5,360,443 5,724,000 Long term investments 205,350 295,749 Deferred taxes 197,627 456,222 Total long-term assets 26,450,325 24,229,237 TOTAL ASSETS $62,731,171 $53,810,444 LIABILITIES CURRENT LIABILITIES Accounts payable $2,547,129 $3,332,174 Other payables and accrued liabilities 2,702,043 2,150,079 Advance for research and development 1,029,657 251,050 Short-term debt 30,352,106 23,915,452 Current portion of long-term debt 1,369,000 - Due to related parties 42,140 27,063 Taxes payable 129,810 352,998 Customer deposits 467,889 335,391 Due to employees 87,141 122,440 Deferred taxes 144,455 172,844 Total current liabilities 38,871,370 30,659,491 Notes payable 1,647,134 1,920,934 Bank loan - 3,717,380 Advance for research and development 54,760 1,065,478 Deferred taxes 970,055 1,019,565 MINORITY INTERESTS 7,871,031 5,177,413 Common stock, $0.001 par value 27,000 27,000 Additional paid-in capital 5,204,352 5,204,352 Retained earnings 7,329,904 4,590,079 Accumulated other comprehensive income 755,565 428,752 Total Shareholders Equity 13,316,821 10,250,183 TOTAL LIABILITIES AND SHAREHOLDERS EQUITY $62,731,171 $53,810,444      S & P Disclaimer   Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version Interim Report      Data Not Available            S & P Disclaimer   Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version Pro Forma Report      Data Not Available            S & P Disclaimer   Aida Pharmaceuticals, Inc. Symbol:  AIDA Click here for a printable version Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2008   1 7,650,000   2008   2 10,900,000   2008   3 11,890,000   2007   1 5,300,000   2007   2 6,420,000   2007   3 7,370,000   2007   Full Year 29,200,000   2006   Full Year 29,640,000   2005   Full Year 24,500,000     Quarterly Net Income, US$ Year Quarter Revenue   2008   1 (20,000)   2008   2 (6,770,000)   2008   3 2,290,000   2007   1 (160,000)   2007   2 (20,000)   2007   3 520,000   2007   Full Year 2,740,000   2006   Full Year 1,454,000   2005   Full Year 1,280,000   2004   Full Year 1,550,000     Quarterly EPS, US$ Year Quarter Revenue   2008   1 Nil   2008   2 (.25)   2008   3 .09   2007   1 (.01)   2007   2 Nil   2007   3 .02   2007   Full Year .10   2006   Full Year .06   2005   Full Year .05      S & P Disclaimer